Nose-to-brain drug delivery: from bench to bedside

Доставка лекарственных средств из носа в мозг: от лаборатории до клинической практики
Isabell Drath, Franziska Richter, Malte Feja
2025-05-19

blood-brain barrier bypassintranasal drug deliverynose-to-brain drug deliveryolfactory and trigeminal pathwaystargeted nanoparticles
There is increasing interest in nose-to-brain delivery as an innovative drug delivery strategy for neurodegenerative disorders such as Parkinson's or Alzheimer's disease. The unique anatomy of the nose-brain interface facilitates direct drug transport via the olfactory and trigeminal pathways to the brain, bypassing the blood-brain barrier. Different administration techniques as well as advanced drug formulations like targeted nanoparticles and thermoresponsive systems have been explored to improve the delivery efficiency and the therapeutic efficacy. This review provides an up-to-date perspective on this fast-developing field, and discusses different studies on safety and pharmacokinetic properties. A thorough evaluation of preclinical and clinical studies reveals both promises and challenges of this delivery method, highlighting approved drugs for the treatment of epilepsy and migraine that successfully utilize intranasal routes. The current landscape of research on nose-to-brain delivery is critically discussed, and a rationale is provided for ongoing research to optimize therapeutic strategies.
1
Approved intranasal treatments for epilepsy and migraine demonstrate successful clinical application of nasal drug delivery.
2
Further research is needed to optimize therapeutic strategies and translate nose-to-brain systems from laboratory studies to clinical practice.
3
Intranasal administration is being investigated for neurodegenerative disorders, including Parkinson’s and Alzheimer’s diseases.
4
Nose-to-brain delivery can transport drugs directly to the brain through olfactory and trigeminal pathways, potentially bypassing the blood-brain barrier.
5
Preclinical and clinical evidence indicates promise but also unresolved safety and pharmacokinetic challenges for nose-to-brain delivery.
6
Targeted nanoparticles, thermoresponsive systems, and optimized administration techniques are being explored to improve delivery efficiency and therapeutic efficacy.

Nose-to-brain drug delivery for neurodegenerative disorders

Delivery efficiency, therapeutic efficacy, safety, pharmacokinetics, and optimization of intranasal drug delivery strategies

Publication Details
Publication Date
2025-05-19
Journal
Publisher
ISSN
Cited by
104
Access Type
Author Information
Authors
Isabell Drath
Franziska Richter
Malte Feja
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat
Make a presentation
100%